TransCode Therapeutics, Inc. (RNAZ) Investor Relations Documents

TransCode Therapeutics, Inc. (RNAZ) investor relations documents from the company's IR site: 4 presentations, 10 press releases; latest deck 2026-03-03. Read in-app with summaries. First-party data.

View Investor Presentation: TransCode Therapeutics (NASDAQ: RNAZ) is an oncology company developing RNA-targeted therapies and vaccines, with lead candidate TTX-MC138 entering Phase 2a.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-06-08Press releaseTransCode Therapeutics to Host R&D Webcast on June 18, 2026
2026-06-03Press releaseTransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC1
2026-05-27Press releaseTransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cance
2026-04-27Press releaseTransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agree
2026-04-07Press releaseTransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into
2026-03-03Press releaseTransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generatio
2026-03-03PresentationView Investor Presentation
2026-02-23Press releaseTransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Furt
2026-02-05Press releaseTransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
2026-01-06Press releaseTransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Gliobl
2025-12-18Presentationhttps://ir.transcodetherapeutics.com/download/TranscodeTherapeuticsDeck121825.pdf
2025-05-23Presentationhttps://ir.transcodetherapeutics.com/download/NDR_Deck_20250523_1110TM_TF.pdf
2024-10-28Presentationhttps://ir.transcodetherapeutics.com/download/Investor+Deck-20241027-2045-TF-copy-TC.pdf
Press releaseTransCode Therapeutics Announces Key Appointments

RNAZ overview · RNAZ earnings · RNAZ financials · RNAZ KPIs · RNAZ ownership · RNAZ peers · RNAZ filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.